KA/EN
Register
Medicines reference
Search
Search
Product

Virbagen Omega

Favourites

Recombinant feline interferon omega · Virbac

4 forms: powder. No registration in force in Georgia.

Forms and doses0 of 4 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
5 MU lyophilisate and solvent, Powder · Cat Cat Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous: 0.2 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
5 MU lyophilisate and solvent, Powder · Dog Dog Canine parvovirosis (enteric form) · Intravenous: 0.5 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Virbagen Omega 5 MU lyophilisate and solvent, Powder

5 x 1 ml
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age
7.6/10
Good
vetman assessment

Virbagen Omega

5 MU lyophilisate and solvent, 5 x 1 ml
Assessed clinical scopeDog · Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age · Intravenous
Care settingHospital treatment alongside intensive parvovirus supportive care
vetman score 7.6/10 Good
Evidence confidence: High Georgia: No · Verified on 21 Oct 2026

A well-documented adjunct for hospitalised canine parvovirosis with meaningful mortality evidence, balanced by predictable monitoring needs.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy8.0/10

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Safety and tolerability6.5/10

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Clinical practicality7.5/10

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during treatment or until recovery; reproductive safety is not established.
  • Monitor blood counts, ALT and concurrent organ failure; transient cytopenias and ALT elevation are very common.
  • Adjunctive therapy only: it does not replace intensive supportive care for canine parvovirosis.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age
6.6/10
Situational / acceptable
vetman assessment

Virbagen Omega

5 MU lyophilisate and solvent, 5 x 1 ml
Assessed clinical scopeCat · Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age · Subcutaneous
Care settingVeterinary-supervised outpatient or hospital course with laboratory monitoring
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 21 Oct 2026

A legitimate but situational FeLV/FIV option: the exact product is well regulated, while efficacy is uneven across the full feline label and the course is burdensome.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy6.0/10

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Safety and tolerability6.0/10

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Clinical practicality5.5/10

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during or after treatment; reproductive safety is not established.
  • Before repeat courses, monitor blood counts, ALT and concurrent hepatic, cardiac or renal failure.
  • Not studied in terminal-stage infection or tumorous FeLV; evidence is materially weaker for FIV than for FeLV.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
  3. AAFP retrovirus 20202020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Recombinant feline interferon omega5000000 IU/vial
Formulation Type
Powder
Administration route
Intravenous, Subcutaneous
Manufacturer
Virbac · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
 EU Yes, veterinary
№ EU/2/01/030/001
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Cat
WeightFeline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous
Any weight 0.2 ml/kg
  • Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous (once daily for 5 days; repeat from days 14 and 60): For FeLV and/or FIV infection in non-terminal clinical stages from 9 weeks of age: 1 MU/kg subcutaneously for three separate 5-day courses starting on days 0, 14 and 60. Reconstitute only with the supplied 1 ml solvent and use immediately. Not tested in terminal-stage infection or tumorous FeLV. Before repeat treatment, monitor concurrent hepatic, cardiac or renal failure. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever, lethargy, diarrhoea or vomiting. Vaccination during and after treatment is contraindicated. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
Dog
WeightCanine parvovirosis (enteric form) · Intravenous
Any weight 0.5 ml/kg
  • Canine parvovirosis (enteric form) · Intravenous (once daily for 3 consecutive days): For enteric canine parvovirosis from one month of age: 2.5 MU/kg intravenously. Reconstitute only with the supplied 1 ml solvent and use immediately. Strict adherence is required. Vaccination during treatment and until recovery is contraindicated. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever and lethargy. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
10 MU lyophilisate and solvent, Powder · Cat Cat Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous: 0.1 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
10 MU lyophilisate and solvent, Powder · Dog Dog Canine parvovirosis (enteric form) · Intravenous: 0.25 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Virbagen Omega 10 MU lyophilisate and solvent, Powder

1 x 1 ml
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age
7.6/10
Good
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 1 x 1 ml
Assessed clinical scopeDog · Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age · Intravenous
Care settingHospital treatment alongside intensive parvovirus supportive care
vetman score 7.6/10 Good
Evidence confidence: High Georgia: No · Verified on 21 Oct 2026

A well-documented adjunct for hospitalised canine parvovirosis with meaningful mortality evidence, balanced by predictable monitoring needs.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy8.0/10

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Safety and tolerability6.5/10

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Clinical practicality7.5/10

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during treatment or until recovery; reproductive safety is not established.
  • Monitor blood counts, ALT and concurrent organ failure; transient cytopenias and ALT elevation are very common.
  • Adjunctive therapy only: it does not replace intensive supportive care for canine parvovirosis.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age
6.6/10
Situational / acceptable
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 1 x 1 ml
Assessed clinical scopeCat · Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age · Subcutaneous
Care settingVeterinary-supervised outpatient or hospital course with laboratory monitoring
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 21 Oct 2026

A legitimate but situational FeLV/FIV option: the exact product is well regulated, while efficacy is uneven across the full feline label and the course is burdensome.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy6.0/10

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Safety and tolerability6.0/10

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Clinical practicality5.5/10

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during or after treatment; reproductive safety is not established.
  • Before repeat courses, monitor blood counts, ALT and concurrent hepatic, cardiac or renal failure.
  • Not studied in terminal-stage infection or tumorous FeLV; evidence is materially weaker for FIV than for FeLV.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
  3. AAFP retrovirus 20202020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Recombinant feline interferon omega10000000 IU/vial
Formulation Type
Powder
Administration route
Intravenous, Subcutaneous
Manufacturer
Virbac · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
 EU Yes, veterinary
№ EU/2/01/030/004
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Cat
WeightFeline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous
Any weight 0.1 ml/kg
  • Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous (once daily for 5 days; repeat from days 14 and 60): For FeLV and/or FIV infection in non-terminal clinical stages from 9 weeks of age: 1 MU/kg subcutaneously for three separate 5-day courses starting on days 0, 14 and 60. Reconstitute only with the supplied 1 ml solvent and use immediately. Not tested in terminal-stage infection or tumorous FeLV. Before repeat treatment, monitor concurrent hepatic, cardiac or renal failure. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever, lethargy, diarrhoea or vomiting. Vaccination during and after treatment is contraindicated. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
Dog
WeightCanine parvovirosis (enteric form) · Intravenous
Any weight 0.25 ml/kg
  • Canine parvovirosis (enteric form) · Intravenous (once daily for 3 consecutive days): For enteric canine parvovirosis from one month of age: 2.5 MU/kg intravenously. Reconstitute only with the supplied 1 ml solvent and use immediately. Strict adherence is required. Vaccination during treatment and until recovery is contraindicated. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever and lethargy. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
10 MU lyophilisate and solvent, Powder · Cat Cat Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous: 0.1 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
10 MU lyophilisate and solvent, Powder · Dog Dog Canine parvovirosis (enteric form) · Intravenous: 0.25 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Virbagen Omega 10 MU lyophilisate and solvent, Powder

2 x 1 ml
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age
7.6/10
Good
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 2 x 1 ml
Assessed clinical scopeDog · Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age · Intravenous
Care settingHospital treatment alongside intensive parvovirus supportive care
vetman score 7.6/10 Good
Evidence confidence: High Georgia: No · Verified on 21 Oct 2026

A well-documented adjunct for hospitalised canine parvovirosis with meaningful mortality evidence, balanced by predictable monitoring needs.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy8.0/10

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Safety and tolerability6.5/10

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Clinical practicality7.5/10

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during treatment or until recovery; reproductive safety is not established.
  • Monitor blood counts, ALT and concurrent organ failure; transient cytopenias and ALT elevation are very common.
  • Adjunctive therapy only: it does not replace intensive supportive care for canine parvovirosis.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age
6.6/10
Situational / acceptable
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 2 x 1 ml
Assessed clinical scopeCat · Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age · Subcutaneous
Care settingVeterinary-supervised outpatient or hospital course with laboratory monitoring
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 21 Oct 2026

A legitimate but situational FeLV/FIV option: the exact product is well regulated, while efficacy is uneven across the full feline label and the course is burdensome.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy6.0/10

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Safety and tolerability6.0/10

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Clinical practicality5.5/10

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during or after treatment; reproductive safety is not established.
  • Before repeat courses, monitor blood counts, ALT and concurrent hepatic, cardiac or renal failure.
  • Not studied in terminal-stage infection or tumorous FeLV; evidence is materially weaker for FIV than for FeLV.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
  3. AAFP retrovirus 20202020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Recombinant feline interferon omega10000000 IU/vial
Formulation Type
Powder
Administration route
Intravenous, Subcutaneous
Manufacturer
Virbac · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
 EU Yes, veterinary
№ EU/2/01/030/003
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Cat
WeightFeline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous
Any weight 0.1 ml/kg
  • Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous (once daily for 5 days; repeat from days 14 and 60): For FeLV and/or FIV infection in non-terminal clinical stages from 9 weeks of age: 1 MU/kg subcutaneously for three separate 5-day courses starting on days 0, 14 and 60. Reconstitute only with the supplied 1 ml solvent and use immediately. Not tested in terminal-stage infection or tumorous FeLV. Before repeat treatment, monitor concurrent hepatic, cardiac or renal failure. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever, lethargy, diarrhoea or vomiting. Vaccination during and after treatment is contraindicated. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
Dog
WeightCanine parvovirosis (enteric form) · Intravenous
Any weight 0.25 ml/kg
  • Canine parvovirosis (enteric form) · Intravenous (once daily for 3 consecutive days): For enteric canine parvovirosis from one month of age: 2.5 MU/kg intravenously. Reconstitute only with the supplied 1 ml solvent and use immediately. Strict adherence is required. Vaccination during treatment and until recovery is contraindicated. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever and lethargy. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
10 MU lyophilisate and solvent, Powder · Cat Cat Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous: 0.1 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
10 MU lyophilisate and solvent, Powder · Dog Dog Canine parvovirosis (enteric form) · Intravenous: 0.25 ml/kg - Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
Details: pack, label wording, sources, registration

Virbagen Omega 10 MU lyophilisate and solvent, Powder

5 x 1 ml
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age
7.6/10
Good
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 5 x 1 ml
Assessed clinical scopeDog · Adjunctive reduction of mortality and clinical signs in enteric canine parvovirosis from one month of age · Intravenous
Care settingHospital treatment alongside intensive parvovirus supportive care
vetman score 7.6/10 Good
Evidence confidence: High Georgia: No · Verified on 21 Oct 2026

A well-documented adjunct for hospitalised canine parvovirosis with meaningful mortality evidence, balanced by predictable monitoring needs.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy8.0/10

Regulatory studies support a clinically meaningful mortality benefit in canine parvovirosis, but interferon is adjunctive and never replaces fluid, electrolyte, antiemetic, nutritional and infection-directed supportive care.

Safety and tolerability6.5/10

Transient cytopenias and ALT elevation are very common and fever or lethargy common; strict dosing, organ-failure assessment and vaccination restrictions are material.

Clinical practicality7.5/10

Three once-daily IV doses are clinically workable for a dog already hospitalised with parvoviral enteritis; reconstitution, venous access, exact weight dosing and immediate use require trained staff.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during treatment or until recovery; reproductive safety is not established.
  • Monitor blood counts, ALT and concurrent organ failure; transient cytopenias and ALT elevation are very common.
  • Adjunctive therapy only: it does not replace intensive supportive care for canine parvovirosis.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age
6.6/10
Situational / acceptable
vetman assessment

Virbagen Omega

10 MU lyophilisate and solvent, 5 x 1 ml
Assessed clinical scopeCat · Labelled treatment of non-terminal feline FeLV and/or FIV infection from nine weeks of age · Subcutaneous
Care settingVeterinary-supervised outpatient or hospital course with laboratory monitoring
vetman score 6.6/10 Situational / acceptable
Evidence confidence: Medium Georgia: No · Verified on 21 Oct 2026

A legitimate but situational FeLV/FIV option: the exact product is well regulated, while efficacy is uneven across the full feline label and the course is burdensome.

Regulatory and scientific credibility8.5/10

The exact 5 MU or 10 MU presentation has current centrally authorised EU product information and a public assessment history; the product is explicitly not registered in the checked Georgian veterinary register.

Clinical efficacy6.0/10

The full labelled FeLV/FIV scope has uneven support: survival benefit was reported in FeLV, whereas FIV mortality was not improved and current feline consensus describes the overall trial base as limited or inconclusive.

Safety and tolerability6.0/10

Transient cytopenias and ALT elevation are very common, with fever, lethargy, diarrhoea or vomiting common; organ-failure monitoring and vaccination restrictions are material across the repeated courses.

Clinical practicality5.5/10

Fifteen subcutaneous injections over three five-day courses starting on days 0, 14 and 60 create substantial visit, restraint, storage and monitoring burden despite a straightforward injection technique.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not vaccinate during or after treatment; reproductive safety is not established.
  • Before repeat courses, monitor blood counts, ALT and concurrent hepatic, cardiac or renal failure.
  • Not studied in terminal-stage infection or tumorous FeLV; evidence is materially weaker for FIV than for FeLV.
Assessment sources
  1. EU SPC 20252025
  2. EMA EPAR2025
  3. AAFP retrovirus 20202020
Assessed: 21 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Recombinant feline interferon omega10000000 IU/vial
Formulation Type
Powder
Administration route
Intravenous, Subcutaneous
Manufacturer
Virbac · France
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
In the register: Virbagen Omega / ვირბაგენ ომეგა
Verified on: 21 Oct 2026
 EU Yes, veterinary
№ EU/2/01/030/002
Verified on: 21 Oct 2026
Controlled in Georgia
Unknown
Cat
WeightFeline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous
Any weight 0.1 ml/kg
  • Feline FeLV/FIV infection, non-terminal clinical stage · Subcutaneous (once daily for 5 days; repeat from days 14 and 60): For FeLV and/or FIV infection in non-terminal clinical stages from 9 weeks of age: 1 MU/kg subcutaneously for three separate 5-day courses starting on days 0, 14 and 60. Reconstitute only with the supplied 1 ml solvent and use immediately. Not tested in terminal-stage infection or tumorous FeLV. Before repeat treatment, monitor concurrent hepatic, cardiac or renal failure. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever, lethargy, diarrhoea or vomiting. Vaccination during and after treatment is contraindicated. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025
Dog
WeightCanine parvovirosis (enteric form) · Intravenous
Any weight 0.25 ml/kg
  • Canine parvovirosis (enteric form) · Intravenous (once daily for 3 consecutive days): For enteric canine parvovirosis from one month of age: 2.5 MU/kg intravenously. Reconstitute only with the supplied 1 ml solvent and use immediately. Strict adherence is required. Vaccination during treatment and until recovery is contraindicated. Very common transient decreases in white cells, platelets and red cells and increased ALT; common transient fever and lethargy. Reproductive safety is not established.
Source:
EU SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Virbagen Omega 5 MU and 10 MU for dogs and cats - Product Information
European Commission / European Medicines Agency / EU Union Product Database, 2025

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗